These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25354137)

  • 1. Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.
    Burden-Teh E; Wootton CI; Williams HC
    Br J Dermatol; 2015 Apr; 172(4):861-6. PubMed ID: 25354137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous leishmaniasis treatment.
    Minodier P; Parola P
    Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
    Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
    J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of cutaneous leishmaniasis in adults and children].
    Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
    Med Trop (Mars); 2005 Nov; 65(5):487-95. PubMed ID: 16465821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral miltefosine to treat new world cutaneous leishmaniasis.
    Soto J; Toledo JT
    Lancet Infect Dis; 2007 Jan; 7(1):7. PubMed ID: 17182338
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran.
    Iraji F; Sadeghinia A
    Ann Trop Med Parasitol; 2005 Jan; 99(1):3-9. PubMed ID: 15701249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
    Pandey K; Pal B; Das VNR; Murti K; Lal CS; Verma N; Bimal S; Ali V; Verma RB; Topno RK; Siddiqi NA; Das P
    Br J Dermatol; 2017 Aug; 177(2):557-559. PubMed ID: 27781268
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
    Carneiro G; Aguiar MG; Fernandes AP; Ferreira LA
    Expert Opin Drug Deliv; 2012 Sep; 9(9):1083-97. PubMed ID: 22724539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cutaneous leishmaniasis with 20% paromomycin ointment.
    Stanimirović A; Stipić T; Skerlev M; Basta-Juzbasić A
    J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):214-7. PubMed ID: 10642059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
    Stojkovic M; Junghanss T; Krause E; Davidson RN
    Int J Dermatol; 2007 Apr; 46(4):385-7. PubMed ID: 17442078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
    Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
    Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of New World cutaneous leishmaniasis with miltefosine.
    Soto J; Berman J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmania tropica in children: a retrospective study.
    Solomon M; Schwartz E; Pavlotsky F; Sakka N; Barzilai A; Greenberger S
    J Am Acad Dermatol; 2014 Aug; 71(2):271-7. PubMed ID: 24775403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for American cutaneous and mucocutaneous leishmaniasis.
    González U; Pinart M; Rengifo-Pardo M; Macaya A; Alvar J; Tweed JA
    Cochrane Database Syst Rev; 2009 Apr; (2):CD004834. PubMed ID: 19370612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical paromomycin for New World cutaneous leishmaniasis.
    Sosa N; Pascale JM; Jiménez AI; Norwood JA; Kreishman-Detrick M; Weina PJ; Lawrence K; McCarthy WF; Adams RC; Scott C; Ransom J; Tang D; Grogl M
    PLoS Negl Trop Dis; 2019 May; 13(5):e0007253. PubMed ID: 31048871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica.
    Killingley B; Lamb LE; Davidson RN
    Ann Trop Med Parasitol; 2009 Mar; 103(2):171-5. PubMed ID: 19208301
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
    Ruiz-Villaverde R; Sánchez-Cano D; Villaverde-Gutierrez C
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):695-6. PubMed ID: 17447994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.